Sign inJoin waitlistJoin the waitlist

Joseph Sparano

Chief, Division of Hematology and Medical Oncology · Icahn School of Medicine at Mount Sinai

Credentials: · · · · ·

History

Division of Hematology and Medical Oncology · Icahn School of Medicine at Mount Sinai
Present
Icahn School of Medicine at Mount Sinai
Present
Montefiore Medical Center/Albert Einstein College of Medicine
Present

Medical Oncology
1985–1987
Internal Medicine
1982–1985
New York Medical College
1978–1982

Research

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Annals of Oncology · 2015 · 2,547 citations
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
New England Journal of Medicine · 2018 · First of 30 authors · 1,827 citations
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
Journal of Clinical Oncology · 2014 · 1,031 citations

George Sledge
49 papers
Kathy Miller
31 papers
Nancy Davidson
31 papers
AW
Antonio Wolff
30 papers
Sunil Badve
30 papers
EP
Edith Perez
26 papers
PW
Peter Wiernik
23 papers
Della Makower
22 papers
LG
Lori Goldstein
22 papers
RA
Richard Ambinder
17 papers
Kevin Kalinsky
16 papers
Ronald Mitsuyasu
15 papers

Grants

Consortium for Advancing Management and Prevention of Cancer in People with HIV
National Cancer Institute · UM1
Contact PI · $154.2M · Icahn School of Medicine at Mount Sinai
2006–2030
Montefiore Academic Community NCORP Program
National Cancer Institute · UG1
Contact PI · $4.9M · Montefiore Medical Center (Bronx, Ny)
2014–2025
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $2.7M · Albert Einstein College of Medicine
1997–2023
AIDS Malignancy Clinical Trials Consortium (AMC)
National Cancer Institute · U01
Project lead · $2.4M · University of California Los Angeles
2006–2015

Clinical trials

Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol
Principal investigator · Not yet recruiting
Eastern Cooperative Oncology Group
2025–2028
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
Principal investigator · Recruiting · Early phase 1
Rima Patel
2025–2027
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Principal investigator · Completed · Phase 1, Phase 2
Joseph Sparano
2019–2025
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
Principal investigator · Terminated · Phase 1, Phase 2
Prescient Therapeutics, Ltd.
2012–2020